This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

Zurück

GIOTRIF® is the first approved irreversible ErbB family blocker6

{
  • The ErbB family of receptors is composed of 4 members: EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB45
  • ErbB family members dimerise with other ErbB family members to signal5
  • EGFR mutations trigger aberrant ErbB family signalling, a key driver in the growth and spread of EGFR M+ NSCLC5
  • Whereas first-generation TKIs, such as gefitinib, reversibly inhibit EGFR, second-generation GIOTRIF® irreversibly blocks signalling from all ErbB family receptors5,7,8

Is this information compelling to you?

Request contact
from Boehringer Ingelheim

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top